Quick Answer
Unicycive Therapeutics, Inc. reported Cash and Equivalents of $29.20 million for fiscal year 2025.
Unicycive Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $29.20M | +11.7% |
| 2024 | $26.14M | +5645.5% |
| 2022 | $455.0K | -97.3% |
| 2021 | $16.58M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $42.70M | — | +91.2% |
| June 30, 2025 | $22.33M | — | +12.9% |
| March 31, 2025 | $19.77M | — | -24.4% |
| December 31, 2024 | $26.14M | — | +82.2% |
| September 30, 2023 | $14.35M | +104.6% | -23.8% |
| June 30, 2023 | $18.82M | +78.0% | -22.7% |
| March 31, 2023 | $24.33M | +78.6% | +5247.7% |
| December 31, 2022 | $455.0K | -97.3% | -93.5% |
- Unicycive Therapeutics, Inc. showed an increase of +11.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Unicycive Therapeutics, Inc.’s cash and equivalents has grown by 76.1% (from $16.58 million to $29.20 million).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: